Form 4: RxSight Executive Ilya Goldshleger Executes Stock Option and Sells Shares

RxSight's Co-President and COO, Ilya Goldshleger, exercised stock options and sold shares on November 29, 2024, according to a recent SEC filing.

Summary

• Ilya Goldshleger, Co-President and Chief Operating Officer of RxSight, Inc., engaged in transactions involving the company's stock on November 29, 2024.
• He exercised stock options to acquire 3,105 shares of common stock at a price of $15.08 per share.
• Concurrently, he sold 3,105 shares of common stock at a price of $46.08 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 3, 2024.
• Following these transactions, Mr. Goldshleger directly owns 42,246 shares and indirectly owns 1,372 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive. It doesn't indicate any positive or negative sentiment, it is a neutral event.

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2024 by the Reporting Person.

Industry Context

This is a routine filing related to executive stock transactions and is common for publicly traded companies. It provides transparency into the trading activities of company insiders.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan is a standard practice for executives to avoid accusations of insider trading.
• The vesting schedule of the stock options, with 1/48th vesting monthly, is a common approach for equity-based compensation.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation and trading activities.

Key Dates

Keywords

stock options, insider trading, Rule 10b5-1, executive compensation, stock sale, RxSight, equity